Remit: To appraise the clinical and cost-effectiveness of atezolizumab within its marketing authorisation for non-small cell lung cancer
| Status | Suspended |
| Decision | Selected |
| Process | TAG |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 11 October 2019 | Suspended. Remit: To appraise the clinical and cost-effectiveness of atezolizumab within its marketing authorisation for non-small cell lung cancer |
| 11 October 2019 | The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps |
For further information on our processes and methods, please see our CHTE processes and methods manual